Clinical Study of Sacubitril Valsartan Sodium Tablets in the Treatment of Peritoneal Dialysis Patients with Chronic Heart Failure
Objective:Clinical study of sacubitril valsartan sodium tablets in the treatment of peritoneal dialysis patients with chronic heart failure.Methods:Sixty patients with chronic heart failure complicated by peritoneal dialysis admitted from May 2021 to April 2023 were selected as the study subjects.They were randomly divided into a control group and a treatment group of 30 cases each using a random number table method.The control group received peritoneal dialysis+basic treatment,while the treatment group received peritoneal dialysis+sacubitril valsartan sodium tablets.The therapeutic effects,renal function,heart function,and adverse reactions of the two groups were compared.Results:After treatment,the NT proBNP,hs CRP,and Scr in the treatment group were lower than those in the control group,and the blood potassium was higher than those in the control group(P<0.05);The LVEDD and LVESD indicators in the treatment group were lower than those in the control group after treatment(P<0.05);There was no statistically significant difference in the incidence of adverse reactions between the two groups after treatment(P>0.05).Conclusion:Sacubitril valsartan sodium tablets can improve patient blood indicators,improve heart function,and have high safety.